Understanding the Rationale for Newer IL-17-Targeted and Emerging Psoriatic Arthritis Therapies: Essentials for Clinicians
Credit(s): 1.00 (60 min)
Release Date: Feb 12, 2020
Expiration Date: Feb 12, 2021
CME / AMA PRA Category 1 Credit™
While there are now a multitude of unique psoriatic arthritis (PsA) therapies to choose from, many patients with PsA still fail to achieve the best possible long-term outcomes. These failures are in part due to a lack of understanding regarding the available targeted PsA therapies and how they address the underlying disease pathology (e.g. the central role of IL-17 in the etiology of PsA). In addition, some clinicians may not yet recognize the impacts different PsA disease domains have on patient quality of life.
This CME activity, “Understanding the Rationale for Newer IL-17-Targeted and Emerging Psoriatic Arthritis Therapies: Essentials for Clinicians,” will help participants recognize and understand the role of IL-17 in the pathophysiology of PsA. The education will review relevant clinical-trial data and explore all the potential uses of already-approved IL-17 inhibitors, as well as novel investigational therapies. Expert faculty will also explore the influence of the various PsA disease domains on patient well-being.
Welcome and Introduction
Rationale for Newer PsA Therapies
Understanding Promising PsA Agents in Late-stage Development
Ensuring Optimal Quality of Life in Patients with PsA
Q&A Session and Activity Roundup
This activity is intended for rheumatologists and others on the rheumatology care team, as these clinicians are the main care providers for patients with PsA.
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.
At the conclusion of this activity, participants should be able to:
Discuss the impact of PsA disease domains on patient QoL
Outline the role of IL-17 in the pathophysiology of PsA
Incorporate recently-approved agents targeting IL-17 into appropriate and effective PsA treatment plans
Evaluate the safety and efficacy data for PsA agents in late-stage clinical development
The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Psoriasis Foundation designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Marina N. Magrey, MD
Associate Professor of Medicine
Case Western Reserve University School of Medicine
Director, Arthritis Clinic and Fellowship Program
MetroHealth Medical Center
Marina N. Magrey, MD is Associate Professor of Medicine at the Case Western Reserve University School of Medicine and the Director of the Arthritis Clinic and Fellowship Program at MetroHealth Medical Center in Cleveland, OH. She previously served as the Medical Director of the MetroHealth Beachwood Medical Center.
Dr. Magrey studied pre-medicine at the Government College for Women in India, then completed her MBBS at the University of Kashmir. She then completed an internship and residency in the Department of Medicine, as well as a fellowship in the Division of Rheumatology, at the Cleveland Clinic.
A member of the American College of Rheumatology, Cleveland Society of Rheumatology, Dr. Magrey serves on the Education Committee of the Spondyloarthritis Research and Treatment Network (SPARTAN). She is the invited member of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the Assessment of Spondyloarthritis International Society (ASAS).
The author or co-author of numerous journal articles, book chapters, and abstracts, Dr. Magrey is also an ad-hoc reviewer for several peer-reviewed journals, including Arthritis Care and Research, Seminars in Arthritis and Rheumatism, International Journal of Rheumatic Diseases, and the Journal of Rheumatology.
Siba P. Raychaudhuri, MD
Chief Rheumatologist, Sacramento VAMC
Professor, Department of Medicine/Rheumatology, Allergy, and Clinical Immunology
University of California-Davis
Siba P. Raychaudhuri, MD is the Chief Rheumatologist at the Sacramento VAMC and a Professor in the Department of Medicine/Rheumatology, Allergy, and Clinical Immunology at the University of California-Davis (UC-Davis) in Davis, CA. He is also the Director of the Rheumatology and Immunology Training Fellowship program at UC-Davis and teaches courses on clinical medicine, immunology, and immuno-pharmacology to medical students, immunology graduate students, and medical residents. Dr. Raychaudhuri established the Psoriasis Research Center at UC-Davis and Sacramento VAMC and has directed one of the most successful psoriasis research programs. He is also Director of the Psoriatic Disease Clinic and, at the Stanford University Medical Center, he worked on cutting-edge immune-based therapies for autoimmune diseases.
Dr. Raychaudhuri earned his MBBS from Medical College Calcutta in India and his medical doctorate from the Post Graduate Institute of Medical Education and Research in India. He completed his postdoctoral fellowship at the Stanford University School of Medicine and Psoriasis Research Institute in Palo Alto, CA. He then completed a fellowship in rheumatology at the Stanford University School of Medicine.
A former member of the Board of Directors of the Spondyloarthritis Research and Treatment Network, Dr. Raychaudhuri serves on the Editorial Boards of Clinical Reviews in Allergy and Immunology and the Indian Journal of Dermatology. He is also an ad-hoc reviewer for numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Investigative Dermatology, Journal of Autoimmunity, and British Journal of Dermatology.
The National Psoriasis Foundation (NPF) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by NPF are required to disclose any relevant financial relationships with any commercial interest to NPF as well as to learners. All conflicts of interest are identified and resolved by NPF in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.
STEERING COMMITTEE DISCLOSURES
The steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Marina N. Magrey, MD: Consultant: Novartis; Advisory Board: Eli Lilly, Novartis; Clinical Trials: AbbVie, UCB Pharma
Siba P. Raychaudhuri, MD: Research: Abbvie, Amgen, Johnson & Johnson, Lilly, Novartis, Pfizer, Sun Pharmacy; Advisor: Johnson & Johnson, Lilly, Novartis, Pfizer
NON-FACULTY CONTENT CONTRIBUTOR DISCLOSURES
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Terry Ann Glauser, MD, MPH; Nicolle Rochino, PharmD, RPh; Blair St. Amand; Andi Agnew: Nothing to disclose
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.
Provided by the National Psoriasis Foundation
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity
Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS) and the New FDA Blueprint
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.